SGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.
SGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.
Investigated for use/treatment in alzheimer's disease, attention deficit/hyperactivity disorder (ADHD), memory loss, and schizophrenia and schizoaffective disorders.
No associated conditions information available.
Stay informed with timely notifications on clinical trials and research advancements.